Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced it has raised $80 million in a Series A financing. Forbion and ...
BOSTON, January 07, 2026--(BUSINESS WIRE)--Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced it has raised $80 ...
The cardiovascular biotech was also named as one of BioSpace’s top startups to watch on Wednesday. Cardiovascular disease biotech Corsera Health, which was named Wednesday as one of BioSpace’s NextGen ...
BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification (CTN) to ...
Advancing a once-annual preventive RNAi medicine designed to reduce the two key drivers of cardiovascular disease: LDL-C and blood pressure Filed application for COR-1004, a novel siRNA targeting ...
– Late-breaking presentation at ESC Congress 2025 confirms that early, persistent lowering of LDL-C and blood pressure leads to improved cardiovascular health outcomes – – Raised over $50 million to ...
Industry giants Clive Meanwell, M.D., and John Maraganore, Ph.D., have unveiled Corsera Health, a new biotech aiming to disrupt the cardiovascular landscape with a once-annual preventive heart disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results